| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Lourdes Vazquez | |
| P2860 | cites work | Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole | Q26782472 |
| Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia | Q28284944 | ||
| Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america | Q34160380 | ||
| Fungal infection prevention after hematopoietic cell transplantation | Q56970496 | ||
| A Double-Blind, Randomized, Placebo-Controlled Trial of Itraconazole Capsules as Antifungal Prophylaxis for Neutropenic Patients | Q56970601 | ||
| Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche | Q74579178 | ||
| Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice | Q87198413 | ||
| Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface | Q95826686 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation | Q34427584 | ||
| Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation | Q34450423 | ||
| Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease | Q34574325 | ||
| Clinical challenge: fatal mucormycotic osteomyelitis caused by Rhizopus microsporus despite aggressive multimodal treatment. | Q35241064 | ||
| Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation | Q35659502 | ||
| Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease | Q35680443 | ||
| Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. | Q35936943 | ||
| Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | Q36028504 | ||
| Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension | Q36171677 | ||
| Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. | Q36662912 | ||
| Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. | Q37046259 | ||
| Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. | Q37220447 | ||
| Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. | Q37344532 | ||
| Pharmacologic and clinical evaluation of posaconazole. | Q37445943 | ||
| The prevalence of antifungal agents administration in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study | Q37552737 | ||
| Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question? | Q37657464 | ||
| Management of drug and food interactions with azole antifungal agents in transplant recipients | Q37775009 | ||
| Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. | Q37900678 | ||
| Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections | Q38053482 | ||
| Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. | Q38284455 | ||
| Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. | Q38620631 | ||
| A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). | Q40439942 | ||
| Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal | Q40475788 | ||
| Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology | Q40615833 | ||
| Prevention and treatment of cancer-related infections | Q42287192 | ||
| Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies | Q43137240 | ||
| Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation | Q43405812 | ||
| Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants | Q44606439 | ||
| European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update | Q46050924 | ||
| Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation | Q46224687 | ||
| Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation | Q46788383 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e2016040 | |
| P577 | publication date | 2016-09-01 | |
| P1433 | published in | Mediterranean journal of hematology and infectious diseases | Q27723406 |
| P1476 | title | Antifungal Prophylaxis in Immunocompromised Patients | |
| P478 | volume | 8 |
| Q64120457 | Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy |
| Q93185050 | Inhaled Amphotericin B as Aspergillosis Prophylaxis in Hematologic Disease: An Update |
| Q50019528 | Liver fungal infections: an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies |
| Q64107228 | Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy |
| Q57055918 | Polymorphisms in receptors involved in opsonic and non-opsonic phagocytosis and the risk of infection in oncohematological patients |
| Q92613666 | Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis |
| Q55313368 | Synergistic and antagonistic effects of immunomodulatory drugs on the action of antifungals against Candida glabrata and Saccharomyces cerevisiae. |
Search more.